{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:31:58Z","timestamp":1761514318061,"version":"3.37.3"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","award":["HHSF223201400188C"],"award-info":[{"award-number":["HHSF223201400188C"]}],"id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["epilepsybehavior.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.yebeh.2018.11.039","type":"journal-article","created":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T20:04:35Z","timestamp":1545249875000},"page":"197-203","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy"],"prefix":"10.1016","volume":"90","author":[{"given":"Sharmila","family":"Das","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenlei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Tung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tricia Y.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James E.","family":"Polli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yebeh.2018.11.039_bb0005","doi-asserted-by":"crossref","first-page":"209","DOI":"10.5698\/1535-7511-16.3.209","article-title":"AES position statement on generic substitution of antiepileptic drugs","volume":"16","author":"Vossler","year":"2016","journal-title":"Epilepsy Curr"},{"key":"10.1016\/j.yebeh.2018.11.039_bb0010","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/epi.13095","article-title":"Generic lamotrigine versus brand-name LAMICTAL bioequivalence in epilepsy patients: a field test of the FDA bioequivalence standard","volume":"56","author":"Ting","year":"2015","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.yebeh.2018.11.039_bb0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S1474-4422(16)00014-4","article-title":"Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial","volume":"15","author":"Privitera","year":"2016","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.yebeh.2018.11.039_bb0020","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1001\/jamaneurol.2017.0492","article-title":"Potential influence of FDA-sponsored studies of antiepilepsy drugs on generic and brand-name formulation prescribing","volume":"74","author":"Krauss","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2018.11.039_bb0025","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1528-1167.2007.01007.x","article-title":"Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes","volume":"48","author":"Andermann","year":"2007","journal-title":"Epilepsia"},{"year":"2000","series-title":"Applied logistic regression","author":"Hosmer","key":"10.1016\/j.yebeh.2018.11.039_bb0030"},{"year":"2014","series-title":"Handbook of biological statistics","author":"McDonald","key":"10.1016\/j.yebeh.2018.11.039_bb0035"},{"year":"2014","series-title":"Handbook of biological statistics","author":"McDonald","key":"10.1016\/j.yebeh.2018.11.039_bb0040"},{"year":"2014","series-title":"Handbook of biological statistics","author":"McDonald","key":"10.1016\/j.yebeh.2018.11.039_bb0045"},{"year":"2009","series-title":"Multiple regression with discrete dependent variables","author":"Orme","key":"10.1016\/j.yebeh.2018.11.039_bb0050"},{"issue":"6","key":"10.1016\/j.yebeh.2018.11.039_bb0055","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1528-1167.2010.02573.x","article-title":"Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability","volume":"51","author":"Bialer","year":"2010","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.yebeh.2018.11.039_bb0060","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1111\/j.1528-1167.2007.01272.x","article-title":"Generic products of antiepileptic drugs (AEDs): is it an issue?","volume":"48","author":"Bialer","year":"2007","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2018.11.039_bb0065","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2012.10.032","article-title":"Generic substitution in the treatment of epilepsy: patient attitudes and perceptions","volume":"26","author":"Ngo","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2018.11.039_bb0070","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/epi.14439","article-title":"Generic antiepileptic drugs-safe or harmful in patients with epilepsy?","volume":"59","author":"Holtkamp","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2018.11.039_bb0075","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.yebeh.2017.05.010","article-title":"Association between switching antiepileptic drug products and healthcare utilization: a systematic review","volume":"73","author":"Kwan","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2018.11.039_bb0080","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.seizure.2018.06.020","article-title":"Brand name to generic substitution of levetiracetam in patients with epilepsy","volume":"60","author":"Gha-Hyun","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2018.11.039_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.seizure.2017.03.012","article-title":"Brand-to-generic levetiracetam switch in patients with epilepsy in a routine clinical setting","volume":"48","author":"Markoula","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.yebeh.2018.11.039_bb0090","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eplepsyres.2017.06.007","article-title":"Comparison of brand versus generic antiepileptic drug adverse event reporting rates in the U.S. Food and Drug Administration adverse event reporting system (FAERS)","volume":"135","author":"Rahman","year":"2017","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.yebeh.2018.11.039_bb0095","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/jamaneurol.2017.0497","article-title":"Bioequivalence between generic and branded lamotrigine in people with epilepsy: the EQUIGEN randomized clinical trial","volume":"74","author":"Berg","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2018.11.039_bb0100","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.eplepsyres.2017.04.017","article-title":"Impact of generic substitution on levetiracetam serum concentration-a prospective study in an outpatient setting","volume":"134","author":"Reimers","year":"2017","journal-title":"Epilepsy Res"},{"issue":"Pt A","key":"10.1016\/j.yebeh.2018.11.039_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.yebeh.2015.08.014","article-title":"Comparative effectiveness of generic versus brand-name antiepileptic medications","volume":"52","author":"Gagne","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"7","key":"10.1016\/j.yebeh.2018.11.039_bb0110","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1021\/acs.molpharmaceut.5b00154","article-title":"Biopharmaceutic risk assessment of brand and generic lamotrigine tablets","volume":"12","author":"Vaithianathan","year":"2015","journal-title":"Mol Pharm"},{"issue":"3","key":"10.1016\/j.yebeh.2018.11.039_bb0115","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/cpt.28","article-title":"Novel bioequivalence approach for narrow therapeutic index drugs","volume":"97","author":"Yu","year":"2015","journal-title":"Clin Pharmacol Ther"},{"author":"Food and Drug Administration","key":"10.1016\/j.yebeh.2018.11.039_bb0120"},{"author":"Food and Drug Administration","key":"10.1016\/j.yebeh.2018.11.039_bb0125"},{"author":"Food and Drug Administration","key":"10.1016\/j.yebeh.2018.11.039_bb0130"},{"key":"10.1016\/j.yebeh.2018.11.039_bb0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.eplepsyres.2016.02.002","article-title":"Response to placebo in clinical epilepsy trials\u2014old ideas and new insights","volume":"122","author":"Goldenholz","year":"2016","journal-title":"Epilepsy Res"},{"issue":"7","key":"10.1016\/j.yebeh.2018.11.039_bb0140","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1007\/s00415-015-8018-7","article-title":"Analysis of nocebo effects of antiepileptic drugs across different conditions","volume":"263","author":"Zaccara","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2018.11.039_bb0145","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.seizure.2016.12.003","article-title":"Nocebo effect in refractory partial epilepsy during pre-surgical monitoring: systematic review and meta-analysis of placebo-controlled clinical trials","volume":"45","author":"Zis","year":"2017","journal-title":"Seizure"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018308011?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505018308011?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T03:40:13Z","timestamp":1565235613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505018308011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":29,"alternative-id":["S1525505018308011"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.11.039","relation":{},"ISSN":["1525-5050"],"issn-type":[{"type":"print","value":"1525-5050"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring generic brittleness and the demographic factors for its susceptibility in patients with epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2018.11.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}